Anxiety: A systematic review of neurobiology, traditional pharmaceuticals and novel alternatives from medicinal plants

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 1, 2014, Pages 150-165

  Gelfuso, Érica Aparecida ^a   Rosa, Daiane Santos ^a   Fachin, Ana Lúcia ^a   Mortari, Márcia Renata ^b   Cunha, Alexandra Olimpio Siqueira ^c   Beleboni, Rene Oliveira ^a  

^a UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; Anxiolytics; Botanicals; Herbal medicines; Neurobiology; Pharmacology

Indexed keywords

ALKALOID DERIVATIVE; ALPHA AMYRIN; BARBITURIC ACID; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA AMYRIN; BUSPIRONE; CLOZAPINE; COUMARIN; ESSENTIAL OIL; FLAVONE; FLAVONOID; FLUOXETINE; GINSENOSIDE; GLYCOSIDE; HYDROXYZINE; KAEMPFEROL; LACTONE; OBOVATOL; OLEANOLIC ACID; PROPRANOLOL; ROSMARINIC ACID; SALVINORIN A; SAPONIN; TANNIN DERIVATIVE; TERPENE DERIVATIVE; TRITERPENE DERIVATIVE; UNINDEXED DRUG; URSOLIC ACID; WOGONIN;

ANXIETY DISORDER; ARTICLE; CHEMICAL STRUCTURE; CLINICAL PHARMACOLOGY; ENERGY METABOLISM; GENERALIZED ANXIETY DISORDER; HUMAN; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPEN FIELD TEST; PANIC; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; SEIZURE; SOCIAL PHOBIA;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; HUMANS; NEUROBIOLOGY; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 84896701090     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990102     Document Type: Article

References (171)

1. Sartori SB, Landgraf R, Singewald N. The clinical implications of mouse models of enhanced anxiety. Fut Neurol 2011; 6(4): 531-71.
2. Lang PJ, Bradley MM, Cuthbert BN. Emotion, motivation, and anxiety: brain mechanisms and psychophysiology. Biol Psychiatry 1998; 44(12): 1248-63.
3. Cisler JM, Olatunji BO, Lohr JM. Disgust, Fear, and the Anxiety Disorders: A Critical Review. Clin Psychol Rev 2009; 29(1): 34-46.
4. Kashdan TB, Zvolensky MJ, McLeish AC. Anxiety sensitivity and affect regulatory strategies: individual and interactive risk factors for anxiety-related symptoms. J Anxiety Disord 2008; 22(3): 429-40.
5. Graeff FG. Anxiety, panic and the hypothalamic-pituitary-adrenal axis. Rev Bras Psiquiatr 2007; 29(Supl I): 3-6.
6. Brandão ML, Vianna DM, Masson S, Santos J. Neural organization of different types of fear: implications for the understanding of anxiety. Rev Bras Psiquiatr 2003; 25(Supl II): 36-41.
7. World Health Organization International Consortium in Psychiatric Epidemiology. Cross-national comparisons of the prevalences and correlates of mental disorders. Bull World Health Organ 2000; 78(4): 413-26.
8. World Health Organization. WHO Library Cataloguing-in-Publication Data, http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/ (Accessed Ago 20 2011).
9. Baldwin DS, Pallanti S, Zwanzger P. Developing a European research network to address unmet needs in anxiety disorders. Neurosci Biobehav Rev 2013; 37(10 Pt 1): 2312-7.
10. Kessler RC, Ormel J, Petukhova M, et al. Development of lifetime comorbidity in the world health organization world mental health surveys. Arch Gen Psychiatry 2011; 68(1): 90-100.
11. Scott KM, Von Korff M, Alonso J, et al. Age patterns in the prevalence of DSM-IV depressive/anxiety disorders with and without physical co- morbidity. Psychol Med 2008; 38(11): 1659-69.
12. Gorman JM. Generalized anxiety disorder. Clin Cornerstone 2001; 3(3): 37-46.
13. American Psychiatric Association. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: Text Revision. 4th ed.; American Psychiatric Association, Ed.; Washington (DC): 2000; p. 943.
14. Mochcovitch MD, Crippa JAS, Nardi AE. Anxiety disorders. Rev Bras Med 2010; 67(11): 390-9.
15. Barchas JD, Faull KF, Quin B, Elliot GR. Biochemical aspects of the psychotic disorders. In: Siegel BW, Agranoff RW, Albers, Molinoff PB, Eds.; Raven Press Ltda; New York 1993; pp. 959-77.
16. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010; 35(1): 169-91.
17. Myers KM, Carlezon WA Jr, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 2011; 36(1): 274-93.
18. Neumann ID, Wegener G, Homberg JR, et al. Animal models of depression and anxiety: what do they tell us about human condition? Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(6): 1357-75.
19. Torres AR, Smaira AI. Obsessive-compulsive disorder is a very heterogeneous. Rev Bras Psiquiatr 2001; 23(Suppl 2): 6-9.
20. Chagas MHN, Nardi AE, Manfro GG, et al. Guidelines of the Brazilian Medical Association for the diagnosis and differential diagnosis of social anxiety disorder. Rev Bras Psiquiatr 2010; 32(4): 444-52.
21. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008; 28(6): 1021-1037.
22. Pregnolato M. Transtorno do pânico e agorafobia: o medo de sentir. PhD Thesis, University São Paulo 2006.
23. Rangè B, Mussoi HS. In: Transtorno de Pânico com Agorafobia; Güntert IB, Colas, C.G, Eds. Casa Psi Livraria, Editora e Gráfica Ltda: São Paulo 2007; pp. 13-14.
24. National Institute of Mental Health. Anxiety Disorders. http://www.nimh.nih.gov/health/publications/anxiety-disorders/nimhanxiety.pdf (accessed Feb 02 2011).
25. Yano Y, Meyer SB, Tung TC. Treatment models for panic disorder. Estud Psicol 2003; 20(3): 125-34.
26. Craske MG, Barlow DH. Transtorno de pânico e agorafobia. In: Barlow DH. Ed.; Artmed: Porto Alegre (RS): 2009; pp. 13-62.
27. Landeira-Fernandez J. In: Neurobiologia dos transtornos de ansiedade. Rangé B. & colaboradores, Eds.; Artmed: Porto Alegre (RS): 2011; pp. 68-81.
28. Margis R, Picon P, Cosner AF, Silveira RO. Stressfull life-events, stress and anxiety. R Psiquiatr 2003; 25(1): 65-74.
29. Kunz-Ebrecht SR, Kirschbaum C, Marmot M, Steptoe A. Differences in cortisol awakening response on work days and weekends in women and men from the Whitehall II cohort. Psychoneuroendocrinology 2004; 29(4): 516-28.
30. Andreatini R, Boerngen-Lacerda R, Zorzetto-Filho D. Pharmacological treatment of generalized anxiety disorder: future perspectives. Rev Bras Psiquiatr 2001; 23(4): 233-42.
31. Sander LD, Porter JR. Influence of cholecystokinin on hypothalamic-stalk median-eminence-extract stimulation of ACTH output from isolated pituitary cells. Life Sci 1982; 31(11): 1103-10.
32. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety: I. preclinical studies. Synapse 1996; 23(1): 28-38.
33. Eison AS, Eison MS. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(1): 47-62.
34. Graeff FG, Zangrossi H Jr. The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and pain disorders. Cent Nerv Syst Agents Med Chem 2010; 10(3): 207-17.
35. Graeff FG, Guimarães FS, De Andrade TG, Deakin JF. Role of the 5-HT in stress, anxiety and depression. Pharmacol Biochem Behav 1996; 54(1): 129-41.
36. Ravindran LN, Stein MB. The Pharmacologic Treatment of Anxiety Disorders: A review of progress. J Clin Psychiatry 2010; 71(7): 839-54.
37. Chaki S, Okubo T, Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Rec Pat CNS Drug Discov 2006; 1(1): 1-27.
38. Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsycho-pharmacol Biol Psychiatry 2008; 32(3): 739-43.
39. Shah YB, Marsden CA. The application of functional magnetic resonance imaging to neuropharmacology. Curr Opin Pharmacol 2004; 4(5): 517-21.
40. Brassen S, Tost H, Hoehn F, et al. Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study. Neurosci Lett 2003; 340(3): 193-6.
41. Hahn A, Stein P, Windischberger C, et al. Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. Neuroimage 2011; 56(3): 881-9.
42. Windischberger C, Lanzenberger R, Holik A, et al. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 2010; 49(2): 1161-70.
43. Paulus MP, Stein MB. Role of functional magnetic resonance imaging in drug discovery. Neuropsychol Rev 2007; 17(2): 179-88.
44. Del-Ben CM, Deakin JF, McKie S, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology 2005; 30(9): 1724-34.
45. Loubinoux I, Boulanouar K, Ranjeva JP, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab 1999; 19(12): 1365-75.
46. Van Der Linden G, Van Heerden B, Warwick J, et al. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(3): 419-38.
47. Hoehn-Saric R, Schlund MW, Wong SH. Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res 2004; 131(1): 11-21.
48. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology 2008; 196(4): 661-72.
49. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 2005; 62(3): 282-8.
50. Aupperle RL, Ravindran L, Tankersley D, et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology 2011; 36(7): 1466-77.
51. Grillon C. Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology 2008; 199(3): 421-37.
52. Viana MB. Freud and Darwin: Signal anxiety as an adaptive reaction to danger. Nat Hum 2010; 12(1): 163-96.
53. Pawlak CR, Ho YJ, Schwarting RK. Animal models of human psychopathology based on individual differences in novelty-seeking and anxiety. Neurosci Biobehav Rev 2008; 32(8): 1544-68.
54. De Paula Soares V, Vicente MA, Biojone C, et al. Distintic behavioral consequences of stress models of depression in the elevated T-maze. Behav Brain Res 2011; 225(2): 590-5.
55. Grundmann O, Nakajima J, Seo S, Butterweck V. Anti-anxiety effects of Apcynum venetum L. in the elevated plus maze test. J Ethnopharmacol 2007; 110(3): 406-11.
56. Vasconcelos SM, Macedo DS, de Melo CT, et al. Central activity of hydroalcoholic extracts from Erythrina velutina and Erythrina mulungu in mice. J Pharm Pharmacol 2004; 56(3): 389-93.
57. Farach FJ, Pruitt LD, Jun JJ, et al. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord 2012; 26(8): 833-43.
58. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx 2006; 3(1): 57-68.
59. Sieghart W, Ramerstorfer J, Sarto-Jackson I, Varagic Z, Ernst M. A novel GABA(A) receptor pharmacology: drugs interacting with the α(+) β(-) interface. Br J Pharmacol 2012; 166(2): 476-85.
60. Jin LJ, Schlesinger F, Song YP, Dengler R, Krampfl K. The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study. Pharmacology 2010; 85(1): 54-62.
61. Sadock BJ. Manual de farmacologia psiquiátrica de Kaplan & Sadock, 4th ed.; Sadock BJ, Sadock VA, Sussman N, Eds.; Artmed: Porto Alegre (RS): 2007; p. 400.
62. Harrison N, Wallace MB, Wit H. In: Barbiturates 2008. Available from: http://www.acnp.org/g4/GN401000173/CH169.html
63. Lazo JS. Goodman & Gilman: As bases farmacológicas da terapêutica. Brunton LL, Lazo JS, Parker KL, Goodman LS, Gilman AG, Eds.; AMGH: Porto Alegre (RS): 2010; p. 1821.
64. Auchewski L, Andreatini R, Galduróz JCF, de Lacerda RB. Evaluation of the medical orientation for the benzodiazepine side effects. Rev Bras Psiquiatr 2004; 26(1): 24-31.
65. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71(7): 839-54.
66. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13(4): 423-37.
67. Mavissakalian MR. Imipramine vs Sertraline in Panic Disorder: 24-Week Treatment Completers. Ann Clin Psychiatry 2003; 15(3-4): 171-80.
68. Schmitt R, Gazalle FK, de Lima MS, et al. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr 2005; 27(1): 18-24.
69. Norman TR, Ellen SR, Burrows GD. Benzodiazepines in anxiety disorders: managing therapeutics and dependence. Med J Aust 1997; 167(9): 490-5.
70. Calandre EP, Iribas JM. Fármacos ansiolíticos e hipnóticos. Rev Asoc Esp Neuropsiq 1992; 12(1): 29-35.
71. Chessick CA, Allen MH, Thase ME, et al. Azapironas para el trastorno de ansiedad generalizada. La Biblioteca Cochrane Plus 2008; 8(2): 1-55.
72. Connor KM, Davidson JR. Generalized anxiety disorder: neurobio-logical and pharmacotherapeutic perspectives. Biol Psychiatry 1998; 44(12): 1286-94.
73. Dere E, Zlomuzica A, De Souza Silva MA, et al. Neuronal histamine and the interplay of memory, reinforcement and emotions. Behav Brain Res 2010; 215(2): 209-20.
74. Naghibi B, Rayatnia F. Co-administration of subeffective anxiolytic doses of diazepam and hydroxyzine in elevated zero-maze in mice. Psychiatry Investig 2011; 8(2): 169-73.
75. Huh J, Goebert D, Takeshita J, Lu BY, Kang M. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord 2011; 13(2): PCC.08r00709.
76. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 1998; 139(4): 402-6.
77. Turner P. Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man. Postgrad Med J 1989; 65(759): 1-6.
78. Tess VLC, Bernik MA. The pharmacological treatment of social phobia. Rev Psiquiatr Clin 2000; 27(6): 323-8.
79. Stahl SM. Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology. J Clin Psychiatry 2003; 5(5): 9-13.
80. Lacerda JCS, Tohen M. The role of atypical antipsychotic agents in the treatment of bipolar disorder: a literature review Acioly LT. Rev Bras Psiquiatr 2002; 24(1): 34-43.
81. Muscatello MR, Spina E, Bandelow B. Baldwin DS. Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol Clin Exp 2012; 27(3): 239-53.
82. National Institutes of Health Office of Alternative Medicine. Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Practice and policy guidelines panel. Arch Fam Med 1997; 6(2): 149-54.
83. Kinrys G, Coleman E, Rothstein E. Natural remedies for anxiety disorders: potential use and clinical applications. Depress Anxiety 2009; 26(3): 259-65.
84. McChesney JD, Venkataraman SK, Henri JT. Plant natural products: Back to the future or into extinction? Phytochemistry 2007; 68: 2015-22.
85. Sousa FCF, Melo CTV, Cito COM, et al. Medicinal plants and their bioactive constituents: A scientifi c review of bioactivity and potential benefi ts in the anxiety disorders in animal models. Rev Bras Farmacogn 2008; 18(4): 642-54.
86. Raza M. A role for physicians in ethnopharmacology and drug discovery. J Ethnopharmacol 2006; 104(3): 297-301.
87. Yunes RA, Pedrosa RC, Cechinel Filho V. Pharmaceutics and phyto-therapics: the need for development of the industry of phyto-pharmaceutics and phytotherapics in Brazil. Quim Nova 2001; 24(1): 147-52.
88. Pereira MAS. Recursos genéticos e conservação de plantas medicinais do Cerrado. Pereira MAS, Eds.; Ribeirão Preto: Legis Summa 2007; p. 356.
89. Andreatini R. Uso de Fitoterápicos na Psiquiatria. Rev Bras Psiquiatr 2000; 22(3): 104-5.
90. Wong AHC, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55(11): 1033-44.
91. Ernst E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine 2006; 13(3): 205-8.
92. Eisenberg DM, David RB, Ettner SL, et al. Trends in alternative medicine use in the United States 1990-1997: results of a follow-up national survey. JAMA 1998; 280(18): 1569-75.
93. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279(19): 1548-53.
94. Maciel MAM, Pinto AC, Veiga Júnior VF. Medicinal plants: the need for multidisciplinary scientific studies. Quim Nova 2002; 25(3): 429-38.
95. Leite JPV. Fitoterapia: bases científicas e tecnológicas. Leite, J.P.V., Eds.; São Paulo: Atheneu 2009; p. 328.
96. Faustino TT, De Almeida RB, Andreatini R. Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies. Rev Bras Psiquiatr 2010; 32(4): 429-36.
97. Clinical Management Series. Natural Medicines Comprehensive Database. http://naturaldatabase.therapeuticresearch.com/ce/ceCourse.aspx?s=ND&cs=&pc=11%2D109&cec=1&pm=5 (Accessed May 05 2012).
98. Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of Generalized Anxiety Disorder: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001; 26(5): 363-7.
99. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010; 9(42): 1-14.
100. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med 2004; 66(4): 607-13.
101. Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutr Metab 2011; 4(3): 211-8.
102. Pakseresht S, Boostani H, Sayyah M. Extract of valerian root (Valeriana officinalis L.) vs placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med 2011; 8: pii: www/j/jcim.2011.8.issue-1/1553-3840.1465/1553-3840.1465.xml
103. Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16(7): 650-4.
104. Nunes A, Sousa M. Use of valerian in anxiety and sleep disorders: what is the best evidence? Acta Med Port 2011; Suppl 4: 961-6.
105. Sarris J, McIntyre E, Camfield DA. Plant-Based Medicines for Anxiety Disorders, Part 1 A Review of Preclinical Studies. CNS Drugs 2013a, 27(3): 207-19.
106. Taylor LH, Kobak KA. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(8): 575-8.
107. Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005a, 20(6): 299-304.
108. Davidson JR, Connor KM. St. John's wort in generalized anxiety disorder: three case reports. J Clin Psychopharmacol 2001; 21(6): 635-6.
109. Kobak KA, Taylor LV, Futterer R, Warner G. St. John's wort in generalized anxiety disorder: three more case reports. J Clin Psychopharmacol 2003; 23(5): 531-2.
110. Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005a, 20(6): 299-304.
111. Kennedy DO, Little W, Haskell CF, Scholey AB. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 2006; 20(2): 96-102.
112. Brown E, Hurd NS, McCall S, Ceremuga TE. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA J 2007; 75(5): 333-7.
113. Di Renzo G. Ginkgo biloba and the central nervous system. Fitoterapia 2000; 71(1): 43-7.
114. Nogueira E, Rosa GJM, Haraguchi M, Vassilieff VS. Anxiolytic effect of Rubus brasiliensis in rats and mice. J Ethnopharmacol 1998; 61(2): 111-7.
115. Nogueira E, Rosa GJM, Vassilieff VS. Involvement of GABAA-benzodiazepine receptor in the anxiolytic effect induced by hexanic fraction of Rubus brasiliensis. J Ethnopharmacol 1998; 61(2): 119-26.
116. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 1994; 47(1): 1-4.
117. Zhang ZJ. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci 2004; 75(14): 1659-99.
118. Da Silva AFS, Andrade JP, Bevilaqua LRM, et al. Anxiolytic-, antidepressant- and anticonvulsant-like effects of the alkaloid montanine isolated from Hippeastrum vittatum. Pharmacol Biochem Behav 2006; 85(1): 148-54.
119. Carr MN, Bekku N, Yoshimura H. Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice. Eur J Pharmacol 2006; 531(1-3): 160-5.
120. Park JH, Cha HY, Seo JJ, et al. Anxiolytic-like effects of ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(6): 895-900.
121. Hartley D, Elsabagh S, File S. Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women. Nutr Neurosci. 2004; 7(5-6): 325-33.
122. Grundmann O, Nakajima JI, Kamata K, Seo S, Butterweck V. Kaempferol from the leaves of Apocynum venetum possesses anxiolytic activities in the elevated plus maze test in mice. Phytomedicine 2009; 16(4): 295-302.
123. Wei XY, Yang JY, Wang JH, Wu CF. Anxiolytic effect of saponins from Panax quinquefolium in mice. J Ethnopharmacol 2007; 111(3): 613-8.
124. Galani VJ, Patel BG. Effect of hydroalcoholic extract of Sphaeranthus indicus against experimentally induced anxiety, depression and convulsions in rodents. Int J Ayurveda Res 2010; 1(2): 87-92.
125. Aragão GF, Carneiro LMV, Junior APF, et al. A possible mechanism for anxiolytic and antidepressant effects of alpha- and beta-amyrin from Protium heptaphyllum (Aubl.) March Pharmacol Biochem Behav 2006; 85(4): 827-34.
126. Yu H, Lee S, Jang C. Involvement of 5-HT1A and GABAA receptors in the anxiolytic-like effects of Cinnamomum cassia in mice. Pharmacol Biochem Behav 2007; 87(1): 164-70.
127. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb® 761 in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2007; 41(6): 472-80.
128. Sarris J, Kavanagh D. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med 2009; 15(8): 827-36.
129. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs 2013b, 27(4): 301-19.
130. Beijamini V, Andreatini R. Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol Res 2003; 48(2): 199-207.
131. Bradley BF, Starkey NJ, Brown SL, Lea RW. Anxiolytic effects of Lavandula angustifolia odour on the Mongolian gerbil elevated plus maze. J Ethnopharmacol 2007; 111(3): 517-25.
132. Xu F, Uebaba K, Ogawa H, et al. Pharmaco-physio-psychologic effect of Ayurvedic oil-dripping treatment using an essential oil from Lav-endula angustifolia. J Altern Complement Med 2008; 14(8): 947-56.
133. Conrad P, Adams C. The effects of clinical aromatherapy for anxiety and depression in the high risk postpartum woman - a pilot study. Complement Ther Clin Pract 2012; 18(3): 164-8.
134. Perry R, Terry R, Watson LK, Ernst E. Is lavender an anxiolytic drug? A systematic review of randomised clinical trials. Phytomedicine 2012; 19(8-9): 825-35.
135. Ibarra A, Feuillere N, Roller M, Lesburgere E, Beracochea D. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. Phytomedicine 2000; 17(6): 397-403.
136. Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res 2009; 23(8): 1075-81.
137. Braida D, Capurro V, Zani A, et al. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 2009; 157(5): 844-53.
138. Hui KM, Huen MS, Wang HY, et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 2002; 64(9): 1415-24.
139. Seo JJ, Lee SH, Lee YS, et al. Anxiolytic-like effects of obovatol isolated from Magnolia obovata: Involvement of GABA/benzodiazepine receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(7): 1363-9.
140. Jiménez-Ferrer E, Herrera-Ruiz M, Ramírez-García R, Herrera-Arellano A, Tortoriello J. Interaction of the natural anxiolytic Galphimine-B with serotonergic drugs on dorsal hippocampus in rats. J Ethnopharmacol. 2011; 137(1): 724-9.
141. Herrera-Arellano A, Jiménez-Ferrer JE, Zamilpa A, et al. Therapeutic effectieffect of Galphimia glauca vs lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial. Planta Med 2012; 78(14): 1529-35.
142. Jung JW, Yoon BH, Oh HR, et al. Anxiolytic-Like Effects of Gastrodia elata and Its Phenolic Constituents in Mice. Biol Pharm Bull 2006a, 29(2): 261-5.
143. Rolland A, Fleurentin J, Lanhers MC, Misslin R, Mortier F. Neurophysiological effects of an extract of Eschscholzia californica Cham. (Papaveraceae). Phytother Res 2001; 15(5): 377-81.
144. Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin 2004; 20(1): 63-71.
145. Flausino OA Jr, Pereira AM, Da Silva Bolzani V, Nunes-de-Souza RL. Effects of Erythrinian Alkaloids Isolated from Erythrina mulungu (Papilionaceae) in Mice Submitted to Animal Models of Anxiety. Biol Pharm Bull 2007; 30(2): 375-8.
146. Rosa DS, Faggion SA, Gavin AS, et al. Erysothrine, an alkaloid extracted from flowers of Erythrina mulungu Mart. ex Benth: evaluating its anticonvulsant and anxiolytic potential. Epilepsy Behav 2012; 23(3): 205-12.
147. Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia 2001; 72(8): 922-6.
148. Sampath C, Holbik M, Krenn L, Butterweck V. Anxiolytic effects of fractions obtained from Passiflora incarnata L. in the elevated plus maze in mice. Phytother Res 2011; 25(6): 789-95.
149. Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. Passiflora incarnata Linneaus as an anxiolytic before spinal anethesia. J Anesth 2012; 26(1): 39-44.
150. Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg 2013; 106(6): 1728-32.
151. De Castro PC, Hoshino A, Da Silva JC, Mendes FR. Possible Anxiolytic Effect of Two Extracts of Passiflora quadrangularis L. in Experimental Models. Phytother Res 2007; 21(5): 481-4.
152. Blainski A, Piccolo VK, Mello JC, De Oliveira RM. Dual effects of crude extracts obtained from Petiveria alliacea L. (Phytolaccaceae) on experimental anxiety in mice. J Ethnopharmacol 2010; 128(2): 541-4.
153. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the Acetonic Kava-Kava extract WS®1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005; 19(3): 183-8.
154. Geier FP, Konstantinowicz T. Kava Treatment in Patients with Anxiety. Phytotherapy 2004; 18(4): 297-300.
155. Boerner RJ, Sommer H, Berger W, et al. Kava-kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder -an 8 week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 2003; 10(Suppl4): 38-49.
156. Cagnacci A, Arangino S, Renzi A, et al. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas 2003; 44(2): 103-9.
157. Thompson R, Ruch W, Hasenöhrl R. Enhanced cognitive performance and cheerful mood by standardized extract of Piper methysticum (Kava-kava). Hum Psychopharmacol. 2004; 19(4): 243-50.
158. Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disordders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord 2004; 78(2): 101-10.
159. Connor K, Payne V, Davidson J. Kava in generalized anxiety disorder: three placebo-controlled ttrial. Int Clin Psychopharmacol 2006; 21(5): 249-53.
160. Peng WH, Hsieh MT, Lee YS, Lin YC, Liao J. Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. J Ethnopharmacol 2000; 72(3): 435-41.
161. Jung JW, Ahn NY, Oh HR, et al. Anxiolytic effects of the aqueous extract of Uncaria rhynchophylla. J Ethnopharmacol 2006b, 108(2): 193-7.
162. Mora S, Diaz-Veliz G, Lungenstrass H, et al. Central nervous system activity of the hydroalcoholic extract of Casimiroa edulis in rats and mice. J Ethnopharmacol 2005b, 97(2): 191-7.
163. Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy of an ethanolic extract of Withania somnifera. Ind J Psychiatry 2000; 42(3): 295-301.
164. Cooley K, Szczurko O, Perri D, et al. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PLoS One 2009; 4(8): E6628.
165. Tabassum I, Siddiqui ZN, Rizvi SJ. Effects of Ocimum sanctum and Camellia sinensis on stress-induced anxiety and depression in male albino Rattus norvegicus. Ind J Pharmacol 2010; 42(5): 283-8.
166. Herrera-Ruiz M, Román-Ramos R, Zamilpa A, Tortoriello J, Jiménez-Ferrer JE. Flavonoids from Tilia americana with anxiolytic activity in plus-maze test. J Ethnopharmacol 2008; 118(2): 312-7.
167. Kumar S, Madaan R, Sharma A. Pharmacological evaluation of bioactive principle of Turnera aphrodisiaca. Ind J Pharm Sci 2008; 70(6): 740-4.
168. Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine 2010; 17(8-9): 674-8.
169. Khom S, Baburin I, Timin E, et al. Valerenic acid potentiates and inhibits GABAA receptors: Molecular mechanism and subunit specificity. Neuropharmacology 2010; 53(1): 178-87.
170. Mora S, Díaz-Véliz G, Millán R, et al. Anxiolytic and antidepressant-like effects of the hydroalcoholic extract from Aloysia polystachya in rats. Pharmacol Biochem Behav 2005; 82(2): 373-8.
171. Hellión-Ibarrola MC, Ibarrola DA, Montalbetti Y, et al. The anxiolytic-like effects of Aloysia polystachya (Griseb.) Moldenke (Verbenaceae) in mice. J Ethnopharmacol 2006; 105(3): 400-8.